

Polio Eradication and Endgame Strategy

IPV supply, financing and Introduction

Michel Zaffran

on behalf of the Immunization Systems

Management Group


SAGE Meeting

5 November 2013

GPEI

Oversight & Management


- Management & Coordination of partners' activities to achieve Objective 2
 - WHO*, UNICEF*, CDC, BMGF, Rotary and GAVI
- * Co-chairs



STATUS OF IPV USING, OPV USING, AND COMBINED IMMUNIZATION

Global use of IPV in primary immunization schedules

MAP DATE: 04 October 2013, Version 1.0



Map Scale (A3): 1:100,000,000

1 cm = 1,000 km

Coordinate System: GCS WGS 1984

Datum: WGS 1984

Units: Degree

Data Source:

Admin. Boundaries: World Health Organization
Base Map: ESRI

Map Production: Public Health Information
and Geographic Information Systems (GIS)
World Health Organization
Data as on

Legend:

- Countries with only IPV in the Primary Immunization Schedule
- Countries with both IPV and OPV in the primary immunization schedule
- Countries with only OPV in the Primary Immunization Schedule
- ⊕ Countries that have announced they will introduce at least 1 dose of IPV

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Coordination of Strategic Plan Objective 2 - Immunization Systems Management Group (IMG) -

Five work streams:

1. Implementation (readiness, supply & demand)

- Co Lead WHO and GAVI

2. Regulatory

- Lead: WHO

3. Financing

- Lead : BMGF


4. Communications

- Co-Lead : WHO and UNICEF

5. Routine immunization Strengthening

- Lead UNICEF

One joint-work plan guides activities across organisations



1. Prioritizing Efforts

Criteria for tiering countries

Tier 1- Highest risk

- Ongoing cVDPV2 transmission or cVDPV2 reported since 2000
 - cVDPV2 outbreak is primary risk following OPV2 cessation
- Wild Polio Virus endemicity
 - Potential to accelerate wild poliovirus eradication by boosting immunity to wild poliovirus types 1 and 3.

Tier 2- Second highest risk

- Any history of cVDPVs (types 1 and 3) since 2000
 - Similar risk factors for VDPV outbreaks for all VDPV serotypes
- Routine immunization coverage less than 80% over past three years
 - Persistent low routine immunization coverage most important predictor of VDPV emergence

Criteria for tiering countries (2)



Tier 3

- Border with countries in Tier 1 that have reported WPV since 2003
 - Predicted future risk of cVDPV2 importations based on trends for importation of wild virus
- WPV importation since 2011.
 - Any WPV importation since 2011 (when India eradicated polio) reflects current risk of importation from remaining endemic countries.

Tier 4


- All other remaining countries using only OPV

Tiers of OPV-using countries & birth cohort



2. Forecast and readiness

Forecasts 2014-2018 : 580m-624m doses



Assumptions :

124 Countries, 1 dose at DTP3; 5 and 10 dose vials (30% and 50% wastage)
DTP3 coverage reached over one year /two years for large countries


Country readiness

- **Regulatory and Policy environment**
 - Mapping of existing IPV licenses,
 - Licensing processes (Acceptance of PQ status, expedited review, other)
 - Mapping of NITAG/ICC discussions
- **Supply chain capacity**
 - Assessment of impact on the cold chain at central and intermediate levels
 - Expedite upgrades
- **Other vaccine introductions**
 - Status of plans for Rotavirus, PCV and HPV introductions
 - Synergies across introduction plans


Cold Chain Capacity

IPV Impact on cold chain is limited, however :

- Countries' systems already stressed- there will not be space to introduce IPV and/or other new vaccines
- Introduction of IPV and other new vaccines is an opportunity to address issues and constraints



Primary store capacity



3. Dialogue with countries

AFRO	<ul style="list-style-type: none"> • IPV in GAVI presentations at September Regional Committee • Briefing of WHO technical staff • Namibia, Swaziland, Botswana possible 2014 introducers
WPRO	<ul style="list-style-type: none"> • June TAG • High level introduction plans by November 15th • No 2014 introductions anticipated (Philippines only possibility)
EMRO	<ul style="list-style-type: none"> • Awaiting Information on financing mechanisms and pricing • Tunisia, Morocco, Libya, Iraq have indicated intent to introduce in 2014. • TAG (21 November)
SEARO	<ul style="list-style-type: none"> • Funding support for operational costs and TA is a priority • Sri Lanka, Maldives could introduce in 2014
EURO	<ul style="list-style-type: none"> • Dedicated session on IPV and DTP combo held at NRA meeting • Combination vaccines may be the preferred option for some countries • Potential introductions in 2014 : Serbia, Macedonia, Moldova
PAHO	<ul style="list-style-type: none"> • TAG July discussions: Working Group formed • Awaiting SAGE recommendations • Clarity on price and financing mechanisms • Argentina and Peru have indicated intent to introduce in 2014.

16 Initial consultations with key countries

Country	Date	Occasion	Outcome
China	March + June	MOH special meeting + WPR TAG in Manila	Schedule options under discussion
India	August	ICMR Expert Committee	1 January 2015
Thailand	August	MOH special meeting	Sequential schedule in 2015
Indonesia	September	MOH special meeting	2015
Vietnam	September	MOH special meeting	2015

Communication

[Immunization service delivery](#)

[Immunization systems and policy](#)

[Vaccines](#)

[Accelerated disease control](#)

[Linking with other interventions](#)

[Publications and media](#)

IPV Introduction and OPV2 Cessation



This site provides information on objective 2 of the [Polio Eradication and Endgame Strategic Plan](#). It contains the rationale for and resources related to the introduction of Inactivated Poliovirus Vaccine (IPV) and cessation of bivalent Oral Polio Vaccine (bOPV).

The site has 5 areas:

LEARN



Understand the rationale behind objective 2 including IPV introduction, OPV cessation and routine immunization strengthening.

PLAN



Plan for IPV introduction including scheduling and financing.

IMMUNIZE



About the Inactivated Poliovirus Vaccine (IPV) including presentation options and safety.

MONITOR



Access the repository to monitor the global status of IPV introduction.

TOOLBOX



Information pack and technical materials for IPV introduction.



[Immunization Home](#)

MEETINGS

Regional Meetings & Key Events
Related to Immunization

June 2013

[Link to list](#)
pdf, 60kb

Global Measles and Rubella Laboratory
Network Meeting

24-26 June 2013

WHO Headquarters, Geneva

Global New and Under-utilized Vaccine
Introduction Surveillance Strategic
Review Meeting

16-20 September 2013

WHO Headquarters, Geneva

SAGE Working Group on Measles and
Rubella

25-26 September 2013

WHO Headquarters, Geneva

GLOSSARY

[Link to IVB glossary](#)

CONTACTS

4. Financing Strategy

Financial support to countries

GAVI Alliance (Board Decision end November)

- Support to all 72 countries irrespective of coverage until 2014 (2018 review for graduating countries)
- Co-financing requirement waived;
- Vaccine introduction grant of 0.80\$ per child

Other countries (under development)

- IPV Subsidies to reach more affordable levels for Middle income countries
- Ideally through pooled procurement channels (i.e. UNICEF SD, PAHO RF)

Budget

GPEI donors and GAVI donors have agreed to support objective 2 implementation costs

- Estimates of \$416 million - \$532 million
- IPV, subsidies, introduction grants and Technical Assistance for IPV implementation, RI strengthening and switch to bOPV
- Leveraging GAVI BP and existing WHO/UNICEF mechanisms and staff where relevant

On-going :

- Validation of technical assistance and staffing needs across all partners (WHO, UNICEF, CDC, GAVI secretariat)
- Confirmation of levels of subsidies and mechanisms to support non-GAVI countries

Thank You !